Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Study findings from Cancer Institute, Division of Pathology broaden understanding of cancer gene therapy
November 11th, 2008
A report, 'Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts,' is newly published data in Clinical Cancer Research. "EML4-ALK is a fusion-type protein tyrosine kinase that is generated by inv(2)(p21p23) in the genome of non-small cell lung cancer (NSCLC). To allow sensitive detection of EML4-ALK fusion transcripts, we have now developed a multiplex reverse transcription-PCR (RT-PCR) system that captures all in-frame fusions between the two genes," researchers in Tokyo, Japan report. "Primers were designed to detect all possible in-frame fusions of EML4 to exon 20 of ALK, and a single-tube multiplex RT-PCR assay was done with total RNA...
Source: Cancer Weekly (2008-11-11)
|
